Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$3,416 Mln
P/E Ratio
--
P/B Ratio
7.49
Industry P/E
--
Debt to Equity
0.12
ROE
-0.23 %
ROCE
-19.66 %
Div. Yield
0 %
Book Value
8.42
EPS
-1.99
CFO
$-0.26 Mln
EBITDA
$-387.89 Mln
Net Profit
$-370.78 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Arcellx Inc (ACLX)
| -17.03 | -8.22 | -3.37 | 22.37 | 81.12 | -- | -- |
|
BSE Sensex*
| 2.08 | 3.87 | 4.39 | 8.33 | 11.78 | 20.18 | 11.16 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
|
|---|---|---|
|
Arcellx Inc (ACLX)
| 37.82 | 79.15 |
|
S&P Small-Cap 600
| 7.01 | 13.89 |
|
BSE Sensex
| 8.10 | 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.78 | 9,808.03 | 20.22 | 23.13 | |
| 290.25 | 8,956.09 | 22.08 | 58.42 | |
| 26.54 | 9,559.25 | -- | -28.77 | |
| 103.22 | 10,030.35 | 30.81 | 14.16 |
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel,... which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1 trials; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. Address: 800 Bridge Parkway, Redwood City, CA, United States, 94065 Read more
Chairman of the Board, CEO & President
Mr. Rami Elghandour
Chairman of the Board, CEO & President
Mr. Rami Elghandour
Headquarters
Redwood City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Arcellx Inc (ACLX) stood at $ 711 Mln as on 31-Dec-24
The share price of Arcellx Inc (ACLX) is $63.63 (NASDAQ) as of 23-Apr-2025 16:00 EDT. Arcellx Inc (ACLX) has given a return of 81.12% in the last 3 years.
Arcellx Inc (ACLX) has a market capitalisation of $ 3,416 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Arcellx Inc (ACLX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Arcellx Inc (ACLX) and enter the required number of quantities and click on buy to purchase the shares of Arcellx Inc (ACLX).
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1 trials; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. Address: 800 Bridge Parkway, Redwood City, CA, United States, 94065
The CEO & director of Mr. Rami Elghandour. is Arcellx Inc (ACLX), and CFO & Sr. VP is Mr. Rami Elghandour.
There is no promoter pledging in Arcellx Inc (ACLX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Arcellx Inc (ACLX) | Ratios |
|---|---|
|
Return on equity(%)
|
-22.84
|
|
Operating margin(%)
|
-96.58
|
|
Net Margin(%)
|
-99.46
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Arcellx Inc (ACLX) was $0 Mln.
$0.51
(
